. 2017 Sep 4;137(1):91–98. doi: 10.1111/ane.12812

Table 3.

Cognitive decline in 134 Parkinson's disease patients, in relation to COMT Val¹⁵⁸Met‐ and DRD2 C⁹⁵⁷T genotype

	H.R. (95% CI)	P‐value
Any cognitive decline (MCI or PDD)
↑No. of COMT ¹⁵⁸Val‐alleles	1.51 (1.11‐2.06)	.009^a
↑No. of DRD2 ⁹⁵⁷T‐alleles	1.64 (1.17‐2.31)	.004^a
COMT ¹⁵⁸Val/Val vs. any Met allele	1.79 (1.06‐3.03)	.030^a
DRD2 ⁹⁵⁷T/T vs. any C allele	2.31 (1.41‐3.79)	<.001^a
COMT ¹⁵⁸Val/Val or DRD2 ⁹⁵⁷T/T	2.46 (1.54‐3.91)	<.001^a
MCI development ^b
COMT ¹⁵⁸Val/Val vs. any Met allele	2.13 (1.11‐4.08)	.023^a
DRD2 ⁹⁵⁷T/T vs. any C allele	2.12 (1.14‐3.94)	.018^a
PDD development
COMT ¹⁵⁸Val/Val vs. any Met allele	1.11 (0.51‐2.45)	.791
DRD2 ⁹⁵⁷T/T vs. any C allele	3.22 (1.64‐6.30)	<.001^a

Hazard Ratios (H.R.) are for risks within 6‐10 years, after correction for age, disease duration, sex, and baseline cognitive status (normal or MCI).

Significant (P < 0.05) after Holm‐Bonferroni correction.

Risk of PD‐MCI was analyzed in the 80 patients who had normal cognition at baseline, while the other outcomes were analyzed in all patients.

COMT, catechol‐O‐methyltransferase; DRD2, dopamine receptor D2; MCI, mild cognitive impairment; PDD, Parkinson's disease dementia; ↑, higher number (0, 1, or 2).